{"title":"冠状动脉介入治疗期间肝素抗凝的最新进展。","authors":"Narins","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Although the equipment, techniques, and adjunctive pharmacologic agents used during coronary angioplasty have evolved dramatically over the past 20 years, unfractionated heparin remains a standard component of the procedure. This article reviews recent data and current concepts regarding the use, importance, and proper dosing of heparin during percutaneous coronary intervention, especially when concomitant platelet glycoprotein IIb/IIIa receptor antagonist therapy is used.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1999-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Update on Heparin Anticoagulation During Coronary Intervention.\",\"authors\":\"Narins\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Although the equipment, techniques, and adjunctive pharmacologic agents used during coronary angioplasty have evolved dramatically over the past 20 years, unfractionated heparin remains a standard component of the procedure. This article reviews recent data and current concepts regarding the use, importance, and proper dosing of heparin during percutaneous coronary intervention, especially when concomitant platelet glycoprotein IIb/IIIa receptor antagonist therapy is used.</p>\",\"PeriodicalId\":80270,\"journal\":{\"name\":\"Current interventional cardiology reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current interventional cardiology reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current interventional cardiology reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Update on Heparin Anticoagulation During Coronary Intervention.
Although the equipment, techniques, and adjunctive pharmacologic agents used during coronary angioplasty have evolved dramatically over the past 20 years, unfractionated heparin remains a standard component of the procedure. This article reviews recent data and current concepts regarding the use, importance, and proper dosing of heparin during percutaneous coronary intervention, especially when concomitant platelet glycoprotein IIb/IIIa receptor antagonist therapy is used.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
